financetom
Business
financetom
/
Business
/
Dollar General beats Q1 sales estimates on demand for pocket-friendly groceries
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dollar General beats Q1 sales estimates on demand for pocket-friendly groceries
May 30, 2024 4:23 AM

(Reuters) - Dollar General ( DG ) beat Wall Street estimates for first-quarter sales on Thursday, as more Americans flocked to its stores for pocket-friendly groceries and essentials at a time when elevated inflation continues to pressure household budgets.

Shares of the Goodlettsville, Tennessee-based company were up 9% before the bell. The stock has gained more than 2% this year, after dropping nearly 45% in 2023.

Dollar General ( DG ) has been focusing on selling relevant merchandise, having more employees at stores and expanding private-label brands, as it looks to attract consumers in the face of rising competition from rivals Walmart and Target and Chinese e-commerce platform Temu.

"These results were driven by strong customer traffic growth and market share gains during the quarter," said CEO Todd Vasos in a statement.

Visits to Dollar General ( DG ) were up 12.6% year-over-year in the first quarter, while rival Dollar Tree saw a 12.4% rise, according to data analytics firm Placer.ai.

The discount retailer's same-store sales rose 2.4% for the quarter, compared with analysts' average estimate of a 1.61% increase, according to LSEG data.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Celldex Therapeutics Initiates Global Phase 3 Trial for Barzolvolimab in Cold Urticaria, Symptomatic Dermographism
Celldex Therapeutics Initiates Global Phase 3 Trial for Barzolvolimab in Cold Urticaria, Symptomatic Dermographism
Mar 10, 2026
10:40 AM EST, 12/09/2025 (MT Newswires) -- Celldex Therapeutics ( CLDX ) said Tuesday it has begun a global phase 3 trial of its experimental drug barzolvolimab in patients with cold urticaria and symptomatic dermographism, which cause intense itching and painful hives. The EMBARQ-ColdU and SD trial will enroll about 240 adults at 75 sites in seven countries, assigning patients...
KeyCorp CEO doubles down on share buybacks, rules out acquisitions
KeyCorp CEO doubles down on share buybacks, rules out acquisitions
Mar 10, 2026
Dec 9 (Reuters) - U.S. regional lender KeyCorp ( KEY ) is not looking to pursue acquisitions despite consolidation in the industry and will use its excess capital for share buybacks, CEO Chris Gorman said on Tuesday. I think there will be consolidation in our industry for a long time, we are not participating, he said at the Goldman Sachs...
Wolfspeed's Silicon Carbide Components to Power Toyota's Onboard Charger Systems
Wolfspeed's Silicon Carbide Components to Power Toyota's Onboard Charger Systems
Mar 10, 2026
10:41 AM EST, 12/09/2025 (MT Newswires) -- Wolfspeed ( WOLF ) said Tuesday that its silicon carbide components will be used to power onboard charger systems for Toyota Motor ( TM ) . Silicon carbide cuts charging times for electric vehicles and minimizes energy loss across the vehicle, Wolfspeed ( WOLF ) said. Financial details of the collaboration were not...
C3.ai Selected by US Army for AI-Driven Contested Logistics Program
C3.ai Selected by US Army for AI-Driven Contested Logistics Program
Mar 10, 2026
10:38 AM EST, 12/09/2025 (MT Newswires) -- C3.ai ( AI ) said Tuesday it was selected by the US Army Rapid Capabilities and Critical Technologies Office to advance AI-driven logistics for Army formations operating in contested environments. The company said its application will be integrated into the US Army brigade command-and-control network to support resupply and distribution operations and streamline...
Copyright 2023-2026 - www.financetom.com All Rights Reserved